Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For type 2 diabetes mellitus. Sold as Steglatro. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Ertugliflozin (sold as Steglatro), first approved Dec 19, 2017, with 1 new use approved and 0 published complete response letters.
First approved: Dec 19, 2017
Applications: 4
New uses approved: 1
Complete response letters: 0
First approved in the EU: Mar 21, 2018
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
STEGLATRO 15 MG TABLET: $11.44 per unitBrand · +0% in a year
STEGLATRO 5 MG TABLET: $11.44 per unitBrand · +0% in a year
Approvals in the EU (EMA)
First approved in the EU 3 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Hikma